8-KItem 5.07 · Shareholder VoteItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements
Bio-Techne shareholders approve Merck KGaA acquisition
Filed with the SEC on · Summarized by InvestorsBot
Bio-Techne shareholders approved the merger agreement with Merck KGaA on September 23, 2026, with 121.9 million votes for and 1.2 million against; 78.55% of eligible shares were represented. The Hart-Scott-Rodino waiting period expired on September 18, and the companies expect the transaction to close by late 2026 or early 2027, subject to remaining regulatory approvals and other customary conditions.